GANX - Gain Therapeutics Inc
IEX Last Trade
1.1
0.030 2.727%
Share volume: 555,763
Last Updated: Fri 30 Aug 2024 09:59:52 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.07
0.03
2.80%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
| Report Date | 2022-05-16 | 2022-08-08 | 2022-11-10 | 2023-03-23 | 2023-05-12 | 2023-08-10 | 2023-11-14 | 2024-03-26 | |
| Assets | |||||||||
| Total Assets | 37.599 M | 31.890 M | 28.326 M | 24.099 M | 21.323 M | 18.261 M | 14.097 M | 18.609 M | |
| Current Assets | 36.392 M | 25.833 M | 24.349 M | 21.091 M | 19.322 M | 17.308 M | 13.242 M | 17.779 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 2.053 M | 1.588 M | 1.619 M | 952.731 K | 1.506 M | 1.115 M | 1.009 M | 984.215 K | |
| Short Term Investments | 2.053 M | 1.588 M | 1.619 M | 952.731 K | 1.506 M | 1.115 M | 1.009 M | 984.215 K | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 34.339 M | 24.245 M | 22.730 M | 20.139 M | 17.816 M | 16.193 M | 12.233 M | 16.795 M | |
| Total Non-current Assets | 1.207 M | 6.057 M | 3.976 M | 3.008 M | 2.001 M | 952.426 K | 855.891 K | 830.463 K | |
| Property Plant Equipment | 106.725 K | 138.909 K | 136.717 K | 144.379 K | 144.636 K | 138.556 K | 127.393 K | 125.962 K | |
| Other Assets | 831.229 K | 745.884 K | 670.261 K | 677.439 K | 627.532 K | 577.505 K | 508.111 K | 477.105 K | |
| Intangible Assets | 220.510 K | 207.667 K | 208.328 K | 213.967 K | 208.913 K | 204.549 K | 189.242 K | 193.375 K | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 37.599 M | 31.890 M | 28.326 M | 24.099 M | 21.323 M | 18.261 M | 14.097 M | 18.609 M | |
| Total liabilities | 5.771 M | 4.873 M | 5.663 M | 5.220 M | 6.184 M | 7.168 M | 6.767 M | 6.031 M | |
| Total current liabilities | 4.217 M | 3.410 M | 4.332 M | 4.125 M | 5.155 M | 5.588 M | 5.763 M | 4.950 M | |
| Accounts Payable | 2.118 M | 948.902 K | 1.019 M | 1.626 M | 2.213 M | 924.390 K | 1.377 M | 1.319 M | |
| Other liabilities | 367.434 K | 376.295 K | 377.782 K | 157.580 K | 164.568 K | 783.167 K | 304.851 K | 402.240 K | |
| Current long term debt | 309.091 K | 299.927 K | 316.231 K | 337.215 K | 341.707 K | 347.434 K | 340.445 K | 348.490 K | |
| Long term debt | 1.186 M | 1.087 M | 952.783 K | 937.042 K | 864.218 K | 796.709 K | 698.398 K | 678.908 K | |
| Other liabilities | 367.434 K | 376.295 K | 377.782 K | 157.580 K | 164.568 K | 783.167 K | 304.851 K | 402.240 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 31.828 M | 27.017 M | 22.663 M | 18.880 M | 15.139 M | 11.093 M | 7.331 M | 12.578 M | |
| Common stock | 11.883 M | 11.883 M | 11.883 M | 11.883 M | 11.935 M | 12.387 M | 12.701 M | 15.022 M | |
| Retained earnings | -20.925 M | -20.925 M | -20.925 M | -20.925 M | -38.516 M | -38.516 M | -38.516 M | -38.516 M |